Our perspectives
in one place
Topic
Selected filters
Clear
News
See allPharmaceutical innovation key to delivering G7 leaders’ growth agenda
The global innovative pharmaceutical industry welcomes the G7 leaders’ commitment to strengthening international cooperation and advancing a balanced and durable growth agenda. IFPMA reiterates that a strong life sciences sector is critical to support these shared objectives.
Read morePharmaceutical industry mobilizes to support response to the Ebola Bundibugyo virus disease outbreak and calls for a system that enables rapid response and sustained R&D investment
The global pharmaceutical industry underlines the commitment of the sector to support the response to the latest Ebolavirus outbreak, and calls for the latest outbreak to be a “wake up call” for negotiators discussing the details of the Pandemic Agreement.
Read moreHigh-Level Virtual Meeting of African Heads of States, Governments and Partners on Ebola Bundibugyo virus disease outbreak
IFPMA Statement ahead of the High-Level Meeting of African Heads of State, Governments and Partners on the Ebola Bundibugyo virus disasese outbreak.
Read more
Pharmaceutical industry calls on G7 to invest in innovation to drive competitiveness, resilience, and growth
Read moreUN Multi-Stakeholder Hearing on Pandemic Prevention, Preparedness, and Response (PPPR)
IFPMA statement at the UN Multi-Stakeholder Hearing on Pandemic Prevention, Preparedness, and Response (PPPR) in New York on 9 June. We share the same objective: a world better prepared to prevent, prepare for, detect, and respond to pandemics. Industry is a core part of that system, engaging in strengthening the health of populations, developing vaccines...
Read morePharmaceutical industry’s response to the Ebola Bundibugyo virus disease outbreak
The latest Ebola Bundibugyo outbreak in Democratic Republic of Congo, Uganda, and neighbouring countries is deeply concerning. Pharmaceutical and biotech companies are working with global partners in a coordinated response. Accelerating the response As the scientific, humanitarian, and global health response accelerates to contain the outbreak, pharmaceutical companies remain central to these efforts. While no...
Read morePublications
See allIFPMA Note for Guidance on educational and scientific events (2026 update)
Collaborations between healthcare professionals (HCPs) and the pharmaceutical industry are essential and ensure that patients have access to the medicines they need and that healthcare professionals have up-to-date comprehensive information about the diseases they treat and the medicines they prescribe.
Read more
Investing in productive economies and resilient societies: The vital role of adult immunization
As populations age and rates of NCDs rise across all demographics, adult immunization represents a high-impact and cost-effective investment in economic growth and societal resilience. This two-pager outlines four policy recommendations to ensure adult immunization is prioritized within national budgets.
Read more
Advancing GMP inspection reliance – from pilots to practice
Around the world, National Regulatory Agencies (NRAs) face mounting pressure to ensure access to and availability of high-quality medicinal products while confronted with an increasing number of sites to inspect, a demand driven by a need to strengthen supply resilience and manage limited inspection resources. This position paper represents the views of the research-based biopharmaceutical...
Read more
Expert insights
See all
Building pandemic readiness through routine vaccination
Read more
The G7 cannot afford to lose its leadership in pharmaceutical innovation
Read more
Innovative medicines as drivers of economic security – A strategic imperative for G7 economies
Read moreResources
See allAdult immunization for healthy workforces and healthy economies in an aging world
IFPMA and the Global Coalition on Ageing (GCOA) outline why vaccination is essential to building healthier workforces and stronger economies in an aging world.
Read more
Streamlining samples management to strengthen health outcomes in Africa
Ensuring the quality, safety, and efficacy of pharmaceutical products is a cornerstone of public health. To meet these high standards, innovative multinational pharmaceutical companies perform rigorous batch release testing for every product, following internationally recognized protocols and approved specifications. However, countries may require additional in-country testing by their National Regulatory Authorities (NRAs) or National Control...
Read more
Our Ethos in Action – Decision-Making Framework Toolkit
IFPMA has developed a Five-Phase Decision-Making Framework, grounded in the IFPMA Ethos or value system, to help companies make decisions that balance business objectives and ethical considerations to meet patient needs and the expectations of the medical community, regulators, and society.
Read more